Inflammatory bowel disease (IBD)-related colorectal cancer (CRC) is responsible for
approximately 2% of the annual mortality from CRC overall, but 10–15% of the annual …

Colon cancer is one of the leading tumours in the world and it is considered among the big
killers, together with lung, prostate and breast cancer. In the recent years very important …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

The global prevalence of cancer is increasing, largely as more patients are living into old
age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] …

The management of patients with IBD requires evaluation with objective tools, both at the
time of diagnosis and throughout the course of the disease, to determine the location …

Background Recently reported risks of colorectal cancer (CRC) in inflammatory bowel
disease (IBD) have been lower than those reported before 2000. The aim of this meta …

Patients with long-standing ulcerative colitis and Crohn's disease have an increased risk of
developing colorectal cancer and patients with small intestinal Crohn's disease are at …

Some autoimmune disorders are increasingly recognized as risk factors for non-Hodgkin
lymphoma (NHL) overall, but large-scale systematic assessments of risk of NHL subtypes …

Cancers of the colon and rectum altogether are the third most common tumour type
worldwide. Cancer of the colon is more frequent than rectal cancer: in high-risk populations …

The innate immune system provides first-line defences in response to invading
microorganisms and endogenous danger signals by triggering robust inflammatory and …